NCT06278506 Resection or Ablation of Small Kidney Tumors
| NCT ID | NCT06278506 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karolinska University Hospital |
| Condition | Kidney Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-01-31 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-01-31 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ablative treatments are believed to have a lower rate of complications, shorter hospital stays, and fewer interventions with benign PAD compared to partial nephrectomies in small kidney cancer lesions. The purpose of the study is to compare complications, the frequency of residual tumors, impact on kidney function, differences in quality of life, and health economic factors in a randomised study. We will also compare the oncological outcomes, including survival and recurrence of kidney cancer.
Eligibility Criteria
Inclusion Criteria: * Age 18 - 99 years * Patient suitable based on clinical status for both ablative treatment and surgery * Primary kidney tumor * Tumor size ≤ 3 cm * Clinical stage of the tumor T1a (no macroscopic vascular or extrarenal invasion) * Tumor location suitable for both ablative treatment and resection * Absence of radiological signs of metastasis * Biopsy with malignant pathological analysis (PAD) * ISUP grade I-III" Exclusion Criteria: * Radiological signs of metastasis * Synchronous kidney tumors * ISUP grade IV or sarcomatoid growth in the biopsy * Other metastasized cancer in the last 5 years * Patient unable to make an informed decision to participate in the study
Contact & Investigator
Anders Kjellman, MD, PhD
PRINCIPAL INVESTIGATOR
Karolinska University Hospital
Frequently Asked Questions
Who can join the NCT06278506 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Kidney Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06278506 currently recruiting?
Yes, NCT06278506 is actively recruiting participants. Contact the research team at anders.kjellman@regionstockholm.se for enrollment information.
Where is the NCT06278506 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT06278506 clinical trial?
NCT06278506 is sponsored by Karolinska University Hospital. The principal investigator is Anders Kjellman, MD, PhD at Karolinska University Hospital. The trial plans to enroll 300 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.